Literature DB >> 21244738

Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline.

Birgit Winther1, Dagobert Buchert, Ronald B Turner, J Owen Hendley, Marion Tschaikin.   

Abstract

BACKGROUND: Intranasal oxymetazoline (OMZ) is used as a decongestant during common colds. Recently, intracellular adhesion molecule (ICAM) 1 receptor expression in vitro has been shown to be diminished by OMZ. ICAM-1 is the major receptor used by rhinovirus to gain entry to human cells. The objective of this study was to assess the effect of OMZ on geometric mean titer of rhinovirus in nasal lavage fluid after rhinovirus inoculation.
METHODS: Volunteers with antibody titers of ≤1:4 to rhinovirus type 39 were enrolled in a randomized, reference-controlled, double-blind study. Beginning 3 hours after intranasal challenge with 100-300 tissue culture infectious dose (TCID)₅₀ of virus, subjects received active 0.05% OMZ (45 μL containing 22.5 μg of OMZ hydrochloride in citrate buffer) or reference control (physiological saline solution [PSS]) three times daily for 5 days. Rhinovirus was detected in fibroblast cultures.
RESULTS: Geometric mean viral titer (log₁₀) in 34 rhinovirus-infected subjects receiving OMZ was 1.49 on day 2 compared with 2.24 in the 38 infected subjects receiving PSS (p = 0.04). On day 3, the mean titers were 1.45 and 2.08, respectively. Median length of viral shedding was 3.3 days (OMZ) and 3.4 (PSS). Duration of clinical illness was 6.1 days in both groups.
CONCLUSION: Topical OMZ decreased viral titer on day 2 during experimental rhinovirus infection in normal volunteers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21244738     DOI: 10.2500/ajra.2010.24.3491

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  6 in total

1.  Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.

Authors:  Mohammad Faheem Khan; Waseem Ahmad Ansari; Tanveer Ahamad; Mohsin Ali Khan; Zaw Ali Khan; Aqib Sarfraz; Mohd Aamish Khan
Journal:  J Mol Model       Date:  2022-07-06       Impact factor: 2.172

Review 2.  Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).

Authors:  Victor B Hsue; Kyohei Itamura; Arthur W Wu; Elisa A Illing; Kevin J Sokoloski; Bree A Weaver; Benjamin P Anthony; Nathan Hughes; Jonathan Y Ting; Thomas S Higgins
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  The role of nasal congestion as a defence against respiratory viruses.

Authors:  Ronald Eccles
Journal:  Clin Otolaryngol       Date:  2020-11-01       Impact factor: 2.597

4.  Acute allergic rhinitis.

Authors:  Robin J Green; Andre Van Niekerk; Marinda McDonald; Raymond Friedman; Charles Feldman; Guy Richards; Fatima Mustafa
Journal:  S Afr Fam Pract (2004)       Date:  2020-10-12

Review 5.  Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections.

Authors:  James A Coultas; John Cafferkey; Patrick Mallia; Sebastian L Johnston
Journal:  J Exp Pharmacol       Date:  2021-07-09

6.  Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Chikara Ogimi; Hu Xie; Wendy M Leisenring; Jane M Kuypers; Keith R Jerome; Angela P Campbell; Janet A Englund; Michael Boeckh; Alpana Waghmare
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.